Skip to main content
. Author manuscript; available in PMC: 2014 Dec 2.
Published in final edited form as: Mol Pharm. 2013 Nov 7;10(12):4527–4533. doi: 10.1021/mp400354y

Figure 3.

Figure 3

(A) In vivo near-infrared imaging of HT29 tumor-bearing mice after injection of h131-Cy5.5, h131-F(ab′)2-Cy5.5 or h131-Fab-Cy5.5. The tumors are indicated by white arrows. (B) Time-fluorescence intensity curves of HT29 tumor for h131-Cy5.5, h131-F(ab′)2-Cy5.5 and h131-Fab-Cy5.5. (C) Ex vivo near-infrared imaging of major organs harvested at 2 d p.i. of h131-Cy5.5, h131-F(ab′)2-Cy5.5 or h131-Fab-Cy5.5. 1 tumor, 2 liver, 3 lung, 4 small intestine, 5 spleen, 6 kidney, and 7 heart. (D) Fluorescence intensity quantification of tumors and major organs at 2 d p.i. of h131-Cy5.5, h131-F(ab′)2-Cy5.5 or h131-Fab-Cy5.5, respectively. All data in B and D are presented as the mean ± standard error of mean (SEM).